image description

Krishna Veeraraghavan


Krishna Veeraraghavan

New York +1-212-558-4000+1-212-558-4000 +1-212-558-3588+1-212-558-3588

Recognized twice as “Dealmaker of the Week” by The American Lawyer, for his work on M&A mega-deals by The Legal 500 and as Leading Lawyer by the IFLR 1000, Krishna Veeraraghavan is a partner and member of S&C’s Mergers and Acquisitions Group, focusing his practice on M&A, corporate governance and private equity matters. He has represented U.S. and non-U.S. companies, special committees, boards of directors and financial advisers in public company transactions, leveraged buyouts and private company sales of subsidiaries and divisions. He is an adjunct professor at Columbia Law School.


  • “2016 Mergers and Acquisitions Report: United States,” International Finance Law Review (co-author)
  • “Merger Market Perspective: Opportunities and Legal Issues in FinTech M&A,” FinTech Law Report (co-author)
  • “The Continuing Importance of Process in Entire Fairness Review: In re Nine Systems,” Deal Lawyers (co-author)
  • “Model Provision for Merger Agreement (Tender Offer),” Practical Law: The Journal (co-author)
  • “2015 Mergers and Acquisitions Report: United States,” International Finance Law Review (co-author)
  • “The Proxy Put and Fiduciary Duties: A Closer Look at Kallick v. SandRidge,” The M&A Lawyer (co-author)
  • “The Uncertain Relationship Between Fiduciary Waivers & the Implied Covenant of Good Faith in Delaware Alternative Entity Law,” The M&A Lawyer (co-author)
  • “Using Option Structures to Reduce Buyer Risk in Pharmaceutical M&A Deals,” Practical Law Company practice note (co-author)
  • “Qualitative Disclosure & Financial Projects: Overshadowed Lessons from In re,” Columbia Law School’s Blue Sky Blog (co-author)
  • “Confidentiality Agreements: Lessons from Delaware,” Bloomberg Law – Practitioner Contributions (co-author)
  • “Recent Delaware Developments: Three Cases with Surprising Outcomes that Reinforce Traditional Fiduciary Principles,” Columbia Law School’s Blue Sky Blog (co-author)
  • “What You Need to Know Before You Receive an Unsolicited Bid,” The M&A Lawyer (co-author)
  • “Memo to the Board of Directors: Preparing for 2013,” Bloomberg/BNA’s Corporate Accountability Report (co-author)
  • “Preparing and Disclosing Financial Projections in Public M&A,” Practical Law: The Journal (co-author)
  • “FCPA for Dealmakers: A Tutorial,” The Deal Pipeline (co-author)
  • “What You Need to Know About the FCPA Before You Do Your Next Deal,” The M&A Lawyer (co-author)

Rankings and Recognitions

  • Chambers USA – Recognized for Corporate/M&A – New York (2016)
  • Law360 – Winner, Life Sciences MVP (2015, 2016)
  • The American Lawyer – Recognized as Transatlantic Rising Star (June 2015)
  • The American Lawyer – Recognized as Dealmaker of the Week for Synageva’s $8.4 billion acquisition by Alexion (May 2015)
  • The American Lawyer – Recognized as Dealmaker of the Week for LabCorp’s $6.1 billion acquisition of Covance (November 2014)
  • The Legal 500 United States – Recognized for M&A: Mega-Deals ($5BN+) (2014)
  • IFLR1000 – Recognized as a Leading Lawyer (2013, 2014, 2015, 2016, 2017)
  • M&A Advisor – Named an M&A Advisor Award Finalist for "Legal Advisor of the Year" (2013)
  • Law360 – Winner, Life Sciences Group Of The Year: Sullivan & Cromwell (2015)
  • New York Law Journal - Recognized as a Rising Star (2015)
  • Selected as one of National Asian Pacific American Bar Association’s (NAPABA) "Best Lawyers Under 40" (2014)
  • M&A Advisor – Recognized in “40 Under 40” ranking of 40 top professionals who have reached a significant level of success in their careers under the age of 40. (March 2012)
  • Law360 – Recognized as a Rising Star for Mergers & Acquisitions (2014, 2015)
  • Diversity & the Bar – Recognized as one of four Rising Stars by the Minority Corporate Counsel Association (MCCA) (March/April 2013)
  • New York Super Lawyers (2011-2016)
  • New York State Bar Association – Named Empire State Counsel Honoree for Pro bono Service (2013, 2014)

Speaking Engagements

  • Panelist, “Special Committees for Evaluating Transactions,” New York County Lawyers’ Association Center for Corporate Governance and The Deal
  • Panelist, “Inbound Into the U.S.: Current Trends in Mergers and Acquisitions in the U.S.” and “Transactions in Key Industry Sectors in the U.S.,”  India - United States Cross Border Investment 2.0: Counseling in Reform Environments
  • Co-presenter, “When International Issues Invade Your Deal,” The University of Texas School of Law 11th Annual Mergers and Acquisitions Institute
  • Co-presenter, “The Art of Negotiation,”
  • Co-presenter, “M&A Non-Disclosure Agreements: Drafting and Key Issues that Can Affect the Course of a Deal,” Practising Law Institute webcast
  • Co-presenter, “Preparing and Disclosing Financial Projections in Public M&A,” Practising Law Institute’s Securities Law Practice Center
  • Co-presenter, “FCPA Due Diligence in Cross-Border Transactions,” Practising Law Institute’s “Hot Topic” briefing
  • Conference Co-Chairman, “Best Practices in Due Diligence: Addressing Due Diligence Challenges in a Rapidly Changing Global M&A Environment,” Executive Enterprise Institute

Professional Activities and Community Involvement

  • American Bar Association – Committee on Mergers and Acquisitions
  • American India Foundation – Board of Trustees
  • Columbia Law School – Adjunct Professor
  • Columbia Law School’s Blue Sky Blog – Advisory Board
  • Columbia Law School – Steering Committee of the Board of Visitors
  • Leadership Council on Legal Diversity (LCLD) – 2013 Fellow
  • South Asian Youth Action (SAYA!) – Board of Directors


In Healthcare & Life Sciences:
  • INC Research in its $7.4 billion pending merger of equals with inVentiv Health
  • Stemcentrx in its $9.8 billion acquisition by AbbVie
  • Teva Pharmaceutical Industries in its $40.5 billion acquisition of Allergan Generics and $50.5 billion unsolicited proposal for Mylan, later withdrawn
  • Dyax in its $5.9 billion acquisition by Shire
  • Concordia Healthcare in its $3.5 billion acquisition of Amdipharm Mercury and its $1.2 billion acquisition of Covis
  • Synageva BioPharma in its $8.4 billion acquisition by Alexion Pharmaceuticals
  • Cyberonics in its $1.5 billion merger with Sorin to create LivaNova
  • LabCorp in its $6.1 billion acquisition of Covance
  • Impax Laboratories in its $700 million acquisition of CorePharma
  • Centerview Partners as financial adviser to Hyperion Therapeutics in its $1.1 billion acquisition by Horizon Pharma and InterMune in its $8.3 billion acquisition by Roche
  • Idenix Pharmaceuticals in its $3.85 billion acquisition by Merck
  • Perrigo Company in its $8.6 billion acquisition of Elan Pharmaceuticals
  • Amgen in its $315 million acquisition of KAI Pharmaceuticals
  • Pharmasset in its $11 billion acquisition by Gilead Sciences
  • IMS in its $5.2 billion sale to investment funds managed by TPG Capital and Canada Pension Plan Investment Board
  • Royal Philips in its $5.1 billion acquisition of Respironics
  • Eastman Kodak in the $2.6 billion sale of its health segment business to Onex
In Technology, Media & Telecommunications:
  • The special committee of Solera Holdings in connection with its $6.5 billion acquisition by Vista Equity Partners
  • AT&T in its $780 million acquisition of Atlantic Tele-Network’s domestic retail wireless business; $950 million sale of AT&T Advertising Solutions and AT&T Interactive to an affiliate of Cerberus Capital Management; and $2.35 billion acquisition of certain wireless assets from Verizon Wireless and its related $240 million sale of certain wireless assets to Verizon Wireless
  • Eastman Kodak in the $527 million sale of its digital imaging patent portfolio to a consortium organized by Intellectual Ventures and RPX
  • Amazon, CSG Systems, CA Technologies, ScanSource, SS&C Technologies and Telstra in connection with various matters
In Consumer & Retail and Industrials:
  • Praxair in connection with its potential $67 billion merger of equals with Linde and $1.1 billion acquisition of NuCO2
  • Lion Capital in its acquisition of minority investment in Authentic Brands Group; acquisition of Spence Diamonds; and $1.5 billion sale of Bumble Bee Foods to Thai Union Frozen Products, later withdrawn
  • Standard Industries in its $2.1 billion acquisition of Braas Monier; $1.1 billion acquisition of Icopal; and acquisition of Quest Construction Products
  • Coleman Cable in its $786 million acquisition by Southwire
  • RR Donnelley in its $620 million acquisition of Consolidated Graphics
  • AB InBev in its $123 billion merger with SABMiller; in its $300 million sale of its Mexican glass production plant to Constellation Brands; $20.1 billion acquisition of the remaining stake in Grupo Modelo; $2.9 billion sale of Compañía Cervecera de Coahuila to Constellation Brands; $1.85 billion sale of a 50% interest in Crown Imports to Constellation Brands; and $2.7 billion sale of its entertainment parks business to an affiliate of Blackstone
  • The Heyman Family in its $3.2 billion sale of International Specialty Products to Ashland
  • NBTY in its $4 billion acquisition by The Carlyle Group
  • The transactions committee of PepsiAmericas in its $2 billion acquisition by PepsiCo
  • Royal Philips in its $2.7 billion acquisition of The Genlyte Group
In Energy:
  • Cheniere Energy in its proposal to the board of directors of Cheniere Energy Partners to acquire the publicly held shares of Cheniere Partners Holdings not already owned by Cheniere in a stock for stock exchange valuing Cheniere Energy Partners at $5.1 billion
  • BHP Billiton in its $15.1 billion acquisition of Petrohawk Energy
  • Dynegy in its proposed acquisition by The Blackstone Group and Icahn Enterprises
  • Constellation Energy in the sale of its downstream natural gas unit to Macquarie Group
  • UBS in the sale of its Canadian-based commodities energy business and global agricultural commodities business to J.P. Morgan                                      
In Real Estate:
  • Special Committee of Forest City Realty Trust in connection with the company's agreement to declassify its common stock and its support agreement with Scopia Capital Management
  • Highgate Hotels in its minority interest investment by  Trilantic Capital Partners
  • Whitehall in its $2.2 billion acquisition of Equity Inns
  • NorthStar Realty Finance in connection with various corporate matters